- SEK1.26bn
- SEK1.13bn
- SEK441.90m
Brief: C-RAD Prepares For Period Of Lower Demand Due To COVID-19
Brief: C-Rad Carries Out Directed New Share Issue Of 2,500,000 Series B Shares, Raising Proceeds Of About SEK 108 Mln
Brief: C-Rad Q4 Operating Result Swings To Loss Of SEK 12.1 Million
Brief: C-Rad: Leave To Appeal Granted In Patent Dispute
Brief: C-Rad Appoints Henrik Bergentoft New CFO
Brief: C-RAD gets penalty imposed by Disciplinary Committee at Nasdaq Stockholm
Brief: C-Rad Q3 Operating Profit At SEK 1.7 Million
Brief: C-Rad Q2 Total Order Intake Up At SEK 64.1 Mln
Brief: C-RAD And Mevion Release Integration For Improved Treatment Quality In Proton Therapy
Brief: Court Confirms C-RAD's Entitlement To Patent Application
Brief: C-Rad Gets Order From MVZ Prof. Dr. Uhlenbrock and Partner In Germany
Swedish stocks: seen opening higher, SEB Q2 profit beats expectations
Brief: C-Rad And Elekta Sign Distribution Deal For North American And Mexican Market
Brief: C-Rad To Focus Its Sales Resources On Its Core Business
Brief: C-Rad Q1 Operating Result Swings To Profit Of SEK 1.2 Million
Brief: C-RAD And OPASCA Announce Strategic Partnership
Brief: C-RAD Signs Agreement With Community Health Network
Brief: C-Rad Names Therése Björklund Interim CFO
Brief: C-Rad Q4 Operating Profit Up At SEK 3.3 Million